Xcovery Holding Co. LLC

Xcovery Holding Co. LLC focuses its clinical research activity on non-small cell lung cancer, with particular attention to ALK-positive NSCLC. The sponsor’s work is centered on treatment options for patients whose disease has already been exposed to prior chemotherapy and who have not previously received an ALK tyrosine kinase inhibitor.

• ALK-positive lung cancer
• Targeted therapy in NSCLC
• Post-chemotherapy treatment settings

The sponsor’s clinical portfolio reflects a concentrated interest in oncology, especially molecularly defined lung cancer populations where targeted treatment approaches are clinically relevant.